Tearsheet

Dianthus Therapeutics (DNTH)

Market Price (5/21/2026): $89.0 | Market Cap: $4.3 Bil
Sector: Health Care | Industry: Biotechnology

Dianthus Therapeutics (DNTH)

Market Price (5/21/2026): $89.0
Market Cap: $4.3 Bil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -26%

Megatrend and thematic drivers
Megatrends include Precision Medicine, and Biotechnology & Genomics. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more.

Meaningful short interest
Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 14.14, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 14%

Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -191 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -14318%

Expensive valuation multiples
P/SPrice/Sales ratio is 3,190x

Stock price has recently run up significantly
6M Rtn6 month market price return is 118%, 12M Rtn12 month market price return is 364%

Weak revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -80%, Rev Chg QQuarterly Revenue Change % is -60%

Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 2102%

Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -9752%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -9767%

Valuation getting more expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 250%

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -8.2%

Key risks
DNTH key risks include [1] uncertain clinical trial outcomes for its lead drug candidate, Show more.

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -26%
1	Megatrend and thematic drivers Megatrends include Precision Medicine, and Biotechnology & Genomics. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more.
2	Meaningful short interest Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 14.14, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 14%
3	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -191 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -14318%
4	Expensive valuation multiples P/SPrice/Sales ratio is 3,190x
5	Stock price has recently run up significantly 6M Rtn6 month market price return is 118%, 12M Rtn12 month market price return is 364%
6	Weak revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -80%, Rev Chg QQuarterly Revenue Change % is -60%
7	Significant share based compensation SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 2102%
8	Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -9752%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -9767%
9	Valuation getting more expensive P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 250%
10	Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -8.2%
11	Key risks DNTH key risks include [1] uncertain clinical trial outcomes for its lead drug candidate, Show more.

Valuation, Metrics & Events

	5/21/26	2025	2024	2023	2022
Share Price CYE	$89.00	$41.21	$21.80	$10.40	$0.40
Market Cap CYE ($ Bil)	4.3	1.9	0.8	0.2	0.0
Total Debt ($ Bil)	0.0	0.0	0.0	0.0	0.0
Total Cash ($ Bil)	1.1	0.4	0.3	0.2	0.1
Enterprise Value ($ Bil)	3.2	1.9	0.8	0.2	0.0
Valuation Ratios
P/S TTM	3,199.8	911.7	123.8	54.5	-
P/EBIT TTM	-22.3	-10.4	-7.6	-3.2	-
P/E TTM	-24.6	-11.4	-9.1	-3.5	-
P/FCF TTM	-32.8	-14.4	-9.9	-4.2	-
Sector Ratios
P/S TTM (Sector)	3.7	4.3	3.8	4.2	4.5
P/EBIT TTM (Sector)	-1.7	-1.7	-1.5	-1.5	-1.3
P/E TTM (Sector)	-1.8	-1.9	-1.7	-1.7	-1.3
P/FCF TTM (Sector)	-1.8	-1.8	-1.5	-1.4	-1.6

	5/21/26	2025	2024
Share Price CYE	$89.00	$41.21	$21.80
Market Cap CYE ($ Bil)	4.3	1.9	0.8
Total Debt ($ Bil)	0.0	0.0	0.0
Total Cash ($ Bil)	1.1	0.4	0.3
Enterprise Value ($ Bil)	3.2	1.9	0.8
Valuation Ratios
P/S TTM	3,199.8	911.7	123.8
P/EBIT TTM	-22.3	-10.4	-7.6
P/E TTM	-24.6	-11.4	-9.1
P/FCF TTM	-32.8	-14.4	-9.9
Sector Ratios
P/S TTM (Sector)	3.7	4.3	3.8
P/EBIT TTM (Sector)	-1.7	-1.7	-1.5
P/E TTM (Sector)	-1.8	-1.9	-1.7
P/FCF TTM (Sector)	-1.8	-1.8	-1.5

	DNTH	S&P 500
REVENUE GROWTH	POOR
Rev LTM ($ Bil)	0.0
Rev Chg Q	-60.2%	8.7%
Rev Chg LTM	-79.5%	7.4%
Rev Chg 3Y Avg	11.4%	5.8%
PROFITABILITY	VERY POOR
Op Inc LTM ($ Bil)	-0.2
CFO LTM ($ Bil)	-0.1
Net Inc LTM ($ Bil)	-0.2
Op Mgn LTM	-14,318.0%	18.4%
CFO/Rev LTM	-9,751.9%	21.1%
Net Inc Mgn	-12,998.5%	13.0%
VALUATION	VERY HIGH
P/S	3,199.8	3.2
P/CFO	-32.8	14.9
P/FCF	-32.8	19.0
P/E	-24.6	23.4
STABILITY	VERY GOOD
Debt/Equity	0.00	0.22
Cash/Assets	0.89	0.07

AI Analysis | Feedback

Metric	Value	Date	Source
Number of Employees	90	10312025	Link
Number of Patents	170	9042025	Link
Number of Clinical Trials	7	11062025	Link
Product Pipeline	[{"product_name": "DNTH103", "indication": "Generalized Myasthenia Gravis (gMG)", "development_phase": "Phase 2"}, {"product_name": "DNTH103", "indication": "Multifocal Motor Neuropathy (MMN)", "development_phase": "Phase 2"}, {"product_name": "DNTH103", "indication": "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)", "development_phase": "Phase 3"}, {"product_name": "DNTH212", "indication": "Systemic Lupus Erythematosus", "development_phase": "Phase 1"}]	11052025	Link

Upcoming
8/06/2026	Earnings Release	Rev: $0.0 Mil (E) EPS: $-0.85 (E)

Price Chart

Return (1M):

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Dianthus Therapeutics (DNTH) stock has gained about 65% since 1/31/2026 because of the following key factors:

1. Positive Phase 3 Clinical Trial Results. On March 9, 2026, Dianthus Therapeutics announced an early "GO" decision for its Phase 3 CAPTIVATE trial of claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). This pivotal milestone was achieved after the trial met its primary responder criteria early, with 20 confirmed responders among fewer than 40 participants in Part A, surpassing the target response rate of 50%. This announcement led to a significant 25.6% jump in the stock price.

2. Successful and Upsized Public Offering. In March 2026, Dianthus Therapeutics completed an upsized underwritten public offering, generating approximately $719 million in gross proceeds. This substantial capital raise significantly strengthened the company's balance sheet, extending its cash runway into 2030 and providing robust funding for its ongoing and planned clinical development programs.

Show more

Holding a concentrated position? Know your true downside before the momentum shifts.

Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The 66.2% change in DNTH stock from 1/31/2026 to 5/20/2026 was primarily driven by a 386.6% change in the company's P/S Multiple.

(LTM values as of)	1312026	5202026	Change
Stock Price ($)	53.39	88.72	66.2%
Change Contribution By:
Total Revenues ($ Mil)	3	1	-56.6%
P/S Multiple	655.6	3,189.7	386.6%
Shares Outstanding (Mil)	38	48	-21.3%
Cumulative Contribution			66.2%

LTM = Last Twelve Months as of date shown

Market Drivers

1/31/2026 to 5/20/2026

	Return	Correlation
DNTH	66.2%
Market (SPY)	7.4%	32.5%
Sector (XLV)	-4.5%	29.9%

Fundamental Drivers

The 153.6% change in DNTH stock from 10/31/2025 to 5/20/2026 was primarily driven by a 1135.6% change in the company's P/S Multiple.

(LTM values as of)	10312025	5202026	Change
Stock Price ($)	34.98	88.72	153.6%
Change Contribution By:
Total Revenues ($ Mil)	5	1	-72.5%
P/S Multiple	258.2	3,189.7	1135.6%
Shares Outstanding (Mil)	36	48	-25.4%
Cumulative Contribution			153.6%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2025 to 5/20/2026

	Return	Correlation
DNTH	153.6%
Market (SPY)	9.3%	20.8%
Sector (XLV)	2.9%	20.1%

Fundamental Drivers

The 306.0% change in DNTH stock from 4/30/2025 to 5/20/2026 was primarily driven by a 2470.4% change in the company's P/S Multiple.

(LTM values as of)	4302025	5202026	Change
Stock Price ($)	21.85	88.72	306.0%
Change Contribution By:
Total Revenues ($ Mil)	6	1	-78.6%
P/S Multiple	124.1	3,189.7	2470.4%
Shares Outstanding (Mil)	35	48	-26.3%
Cumulative Contribution			306.0%

LTM = Last Twelve Months as of date shown

Market Drivers

4/30/2025 to 5/20/2026

	Return	Correlation
DNTH	306.0%
Market (SPY)	35.2%	21.9%
Sector (XLV)	6.6%	25.5%

Fundamental Drivers

null
null

Market Drivers

4/30/2023 to 5/20/2026

	Return	Correlation
DNTH	11223.5%
Market (SPY)	85.2%	-0.3%
Sector (XLV)	15.8%	1.4%

Return vs. Risk

Price Returns Compared

	2021	2022	2023	2024	2025	2026	Total [1]
Returns
DNTH Return	-43%	-91%	2533%	110%	89%	108%	993%
Peers Return	-2%	19%	20%	-12%	45%	-3%	73%
S&P 500 Return	27%	-19%	24%	23%	16%	7%	96%
Monthly Win Rates [3]
DNTH Win Rate	42%	25%	42%	58%	58%	80%
Peers Win Rate	47%	58%	57%	43%	67%	40%
S&P 500 Win Rate	75%	42%	67%	75%	67%	60%
Max Drawdowns [4]
DNTH Max Drawdown	-69%	-93%	-51%	-37%	-45%	-13%
Peers Max Drawdown	-28%	-19%	-17%	-28%	-25%	-17%
S&P 500 Max Drawdown	-5%	-25%	-10%	-8%	-19%	-9%

[1] Cumulative total returns since the beginning of 2021
[2] Peers: JNJ, AMGN, VRTX, REGN, IONS.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/20/2026 (YTD)

Event	DNTH	S&P 500
2025 US Tariff Shock
% Loss	-36.3%	-18.8%
% Gain to Breakeven	57.1%	23.1%
Time to Breakeven	134 days	79 days
Summer-Fall 2023 Five Percent Yield Shock
% Loss	-11.1%	-9.5%
% Gain to Breakeven	12.5%	10.5%
Time to Breakeven	7 days	24 days
2023 SVB Regional Banking Crisis
% Loss	-26.8%	-6.7%
% Gain to Breakeven	36.7%	7.1%
Time to Breakeven	117 days	31 days
2022 Inflation Shock & Fed Tightening
% Loss	-81.5%	-24.5%
% Gain to Breakeven	440.8%	32.4%
Time to Breakeven	488 days	427 days
2020 COVID-19 Crash
% Loss	-53.8%	-33.7%
% Gain to Breakeven	116.3%	50.9%
Time to Breakeven	348 days	140 days
Q4 2018 Fed Policy Error / Growth Scare
% Loss	-49.8%	-19.2%
% Gain to Breakeven	99.1%	23.8%
Time to Breakeven	61 days	105 days

Compare to JNJ, AMGN, VRTX, REGN, IONS

In The Past

Dianthus Therapeutics's stock fell -36.3% during the 2025 US Tariff Shock. Such a loss loss requires a 57.1% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

Event	DNTH	S&P 500
2025 US Tariff Shock
% Loss	-36.3%	-18.8%
% Gain to Breakeven	57.1%	23.1%
Time to Breakeven	134 days	79 days
2023 SVB Regional Banking Crisis
% Loss	-26.8%	-6.7%
% Gain to Breakeven	36.7%	7.1%
Time to Breakeven	117 days	31 days
2022 Inflation Shock & Fed Tightening
% Loss	-81.5%	-24.5%
% Gain to Breakeven	440.8%	32.4%
Time to Breakeven	488 days	427 days
2020 COVID-19 Crash
% Loss	-53.8%	-33.7%
% Gain to Breakeven	116.3%	50.9%
Time to Breakeven	348 days	140 days
Q4 2018 Fed Policy Error / Growth Scare
% Loss	-49.8%	-19.2%
% Gain to Breakeven	99.1%	23.8%
Time to Breakeven	61 days	105 days

Compare to JNJ, AMGN, VRTX, REGN, IONS

In The Past

Dianthus Therapeutics's stock fell -36.3% during the 2025 US Tariff Shock. Such a loss loss requires a 57.1% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Dianthus Therapeutics (DNTH)

Business Description Analogies Products Customers Suppliers Management Key Risks Emerging Threats Market Size Revenue Drivers Capital Allocation

Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that cause acute myeloid leukemia and myelodysplastic syndromes, which is under Phase I/II clinical trial; CD45-antibody drug conjugate that targets HSCs and immune cells, which is in investigational new drug application enabling studies for potential use as a single-agent in autoimmune diseases and hematology-oncology transplants; and MGTA-145 that is in Phase II clinical trial for use in autologous and allogeneic transplants. The company also has a cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing. Magenta Therapeutics, Inc. has a research and clinical collaboration agreement with AVROBIO, Inc. for the treatment of lysosomal storage disorders; and Beam Therapeutics, Inc. to evaluate the potential utility of MGTA-117 for conditioning of patients with sickle cell disease and beta-thalassemia. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

AI Analysis | Feedback

null

AI Analysis | Feedback

MGTA-117: An anti-CD117 antibody therapy designed to target hematopoietic stem cells and genetically mutated stem cells for conditioning in blood cancers and genetic diseases.
CD45-antibody drug conjugate: An investigational therapy targeting hematopoietic stem cells and immune cells for potential use in autoimmune diseases and hematology-oncology transplants.
MGTA-145: A CXCR2 agonist mobilizing stem cells currently in Phase II clinical trial for use in autologous and allogeneic transplants.
E478: A small molecule aryl hydrocarbon receptor antagonist being developed for stem cell-based gene therapy and genome editing.

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

Marino Garcia, President & Chief Executive Officer, Board Member

Marino Garcia has served as President and Chief Executive Officer of Dianthus Therapeutics since November 2021. Prior to joining Dianthus, Mr. Garcia was Senior Vice President, Corporate and Business Development at Zealand Pharma A/S from October 2018 to October 2021. He previously served as Executive Vice President, Chief Strategy Officer at Synergy Pharmaceuticals from 2014 to 2018. Before Synergy, Mr. Garcia was Head of Business Development for Aptalis Pharma, which was acquired by Forest Laboratories (now Allergan, an AbbVie Company) in 2014. He also served as Vice President, US Commercial Operations and Global New Product Development at Aspreva Pharmaceuticals, which was acquired by Vifor Pharma in 2007. Mr. Garcia started his career in various commercial and strategic roles at large, multinational biopharmaceutical companies, including Merck & Co., Pfizer Inc., and Eli Lilly and Co.. He is known as a "dealmaker" CEO, with a background in corporate development evident in the company's capital raises and strategic reverse merger.

Ryan Savitz, Chief Financial Officer & Chief Business Officer, Treasurer

Ryan Savitz is the Chief Financial Officer and Chief Business Officer at Dianthus Therapeutics, Inc. He was appointed CFO in June 2022 at Former Dianthus, becoming CFO of the combined company at the September 11, 2023 reverse merger, and was promoted to Chief Business Officer on February 7, 2024. Prior to Dianthus, he spent 12 years in Citigroup's Healthcare Investment Banking, where he advised on biopharma capital raising and mergers & acquisitions.

Simrat Randhawa, M.D., Executive Vice President, Head of R&D

Dr. Simrat Randhawa brings over 20 years of clinical practice and pharmaceutical industry experience to Dianthus Therapeutics. He most recently served as Senior Vice President of Clinical and Medical Affairs at Aurinia Pharmaceuticals, an autoimmune-focused company. Dr. Randhawa has held several senior commercial and medical leadership roles in the autoimmune and rare disease areas at large pharmaceutical and biotech companies such as Novartis and Biomarin. He has also supported business development opportunities and integration needs in the healthcare sector while at McKinsey.

Ronny Hashmonay, M.D., Chief Development and Medical Affairs Officer

Dr. Ronny Hashmonay has over 20 years of international experience in the healthcare and pharmaceutical industries. He most recently served as Global Head of Business Transformation for Novartis. In his prior role as Chief Digital Officer at Novartis United States, he spearheaded digital transformation and strategic corporate health tech partnerships. As a member of the Novartis U.S. Executive Committee, Dr. Hashmonay led multiple teams as Head of Business Innovation, Head of Business Development and Licensing, and Head of Launch Excellence.

Edward Carr, Chief Accounting Officer

Edward Carr serves as the Chief Accounting Officer at Dianthus Therapeutics, Inc..

AI Analysis | Feedback

Key Risks to Dianthus Therapeutics (DNTH)

Clinical Trial and Regulatory Risk: Dianthus Therapeutics is a clinical-stage biotechnology company, and the success of its business hinges on the successful completion of its clinical trials and subsequent regulatory approvals for its drug candidates. There is no assurance that ongoing or future clinical trials, such as Part B of the Phase 3 CAPTIVATE study for claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), will achieve positive outcomes or meet endpoints in a statistically significant manner, which could prevent the company from filing for or receiving regulatory approval (e.g., Biologics License Application with the FDA). Any safety signals related to its complement system-targeting drugs could also lead to regulatory delays or warnings.
Commercialization and Market Competition Risk: Dianthus Therapeutics currently lacks a commercial infrastructure. Building this infrastructure or securing a suitable partner to market and distribute its products, if approved, is a high-stakes endeavor. The company also operates in a highly competitive industry, with established players and other companies developing similar therapies. The entry of more drugs into the markets for conditions like CIDP and generalized Myasthenia Gravis (gMG) could lead to competitive pricing pressures and impact long-term margins. Competitors with greater financial resources and established market presence could hinder Dianthus's market penetration.
Financial Vulnerability: As a clinical-stage company, Dianthus Therapeutics has not yet commercialized any products and continues to incur significant losses. While the company has a substantial cash runway, its long-term financial health is dependent on its ability to secure additional capital, manage expenses effectively, and ultimately achieve commercial success with its product candidates. Without a stable revenue stream from commercialized products, the company remains financially vulnerable, and its future success relies on the commercial viability of its pipeline.

AI Analysis | Feedback

null

AI Analysis | Feedback

Dianthus Therapeutics' main product, claseprubart (DNTH103), is being developed for severe autoimmune and inflammatory diseases. The company's pipeline targets generalized myasthenia gravis (gMG), chronic inflammatory demyelinating polyneuropathy (CIDP), and multifocal motor neuropathy (MMN). The estimated market opportunity for DNTH103 is nearly $20 billion. Specifically for generalized myasthenia gravis (gMG), a key indication for DNTH103, the total addressable market is projected to reach $12 billion by 2030. These market sizes are implied to be global.

AI Analysis | Feedback

Dianthus Therapeutics (DNTH), a clinical-stage biotechnology company, anticipates its future revenue growth over the next 2-3 years to be primarily driven by the successful advancement and potential commercialization of its pipeline of novel antibody complement therapeutics for severe autoimmune and inflammatory diseases. As a company with a trailing 12-month revenue of approximately $2.04 million as of December 31, 2025, its revenue generation is currently limited, typical for a biotechnology company at its stage.

The key drivers for Dianthus Therapeutics' future revenue growth are:

Commercialization of Claseprubart (DNTH103) for Generalized Myasthenia Gravis (gMG): Dianthus' lead candidate, claseprubart, a C1s antibody, is being developed for gMG. Positive Phase 2 data was reported in September 2025, and the company plans to initiate a Phase 3 trial in mid-2026, with top-line data expected in the second half of 2028. Successful completion of this pivotal trial and subsequent market approval and launch would represent a significant revenue opportunity in the multibillion-dollar gMG market.
Commercialization of Claseprubart (DNTH103) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): The company's Phase 3 CAPTIVATE trial for claseprubart in CIDP achieved its early responder target in March 2026, suggesting a strong path toward a single pivotal Biologics License Application (BLA) strategy. Guidance for Part B top-line data is anticipated by year-end 2026. The CIDP market is also identified as a large and growing multibillion-dollar opportunity.
Expansion of Claseprubart (DNTH103) into Additional Indications, specifically Multifocal Motor Neuropathy (MMN): Dianthus operates on a "pipeline-in-a-product" model, aiming to leverage claseprubart across multiple indications. Beyond gMG and CIDP, the Phase 2 MoMeNtum trial for claseprubart in MMN is ongoing, with top-line results expected in the second half of 2026. Positive results and eventual commercialization in MMN would further broaden the market reach and revenue potential of claseprubart.
Advancement and Potential Commercialization of DNTH212: Dianthus is also developing DNTH212, an investigational bifunctional fusion protein for other autoimmune diseases, including systemic lupus erythematosus. A Phase 1 study in China is underway, with top-line results in healthy volunteers expected in the second half of 2026. The successful clinical development and eventual market entry of DNTH212 would diversify the company's product portfolio and open new revenue streams.

AI Analysis | Feedback

Share Issuance

Dianthus Therapeutics closed an upsized underwritten public offering in March 2026, raising approximately $719 million in aggregate gross proceeds by selling 8,470,989 common shares and 402,468 pre-funded warrants.
In September 2025, the company completed an upsized $288 million underwritten public offering.
Dianthus Therapeutics announced a private investment in public equity (PIPE) financing in January 2024, expected to result in gross proceeds of approximately $230 million.

Inbound Investments

In September 2023, Dianthus Therapeutics completed a reverse merger with Magenta Therapeutics, providing a cash infusion of $180 million and a Nasdaq listing.
The company emerged from stealth in May 2022 with a $100 million Series A financing, backed by investors such as 5AM Ventures and Fidelity.
In January 2024, Dianthus received approximately $230 million in gross proceeds from a PIPE financing with participation from new and existing investors, including Bain Capital Life Sciences and RA Capital Management.

Outbound Investments

In October 2025, Dianthus Therapeutics acquired an exclusive global license for DNTH212 from Nanjing Leads Biolabs, involving an upfront payment of $30 million and potential milestone payments up to $1 billion.

Capital Expenditures

Research and development (R&D) expenses for the year ended December 31, 2025, were $145.6 million, an increase from $83.1 million in 2024.
The increase in R&D expenses in 2025 was primarily driven by higher clinical costs, upfront and clinical development milestones for DNTH212, and increased headcount to support Phase 2 and Phase 3 development.
As of December 31, 2025, Dianthus reported $514.4 million in cash, cash equivalents, and investments, projected to fund operations into 2028, covering clinical and preclinical development activities, commercial readiness, working capital, and general corporate purposes.

Interactive Breakdown

null

null

Better Bets vs. Dianthus Therapeutics (DNTH)

null

Latest Trefis Analyses

	Title	Date
0	DASHBOARDS
1	Dianthus Therapeutics Earnings Notes	12/16/2025
2	How Low Can Dianthus Therapeutics Stock Really Go?	10/17/2025
3	Day 7 of Gains Streak for Dianthus Therapeutics Stock with 61% Return (vs. 74% YTD) [9/10/2025]	09/11/2025
4	Dianthus Therapeutics (DNTH) Operating Cash Flow Comparison	02/17/2025
5	Dianthus Therapeutics (DNTH) Net Income Comparison	02/15/2025
6	Dianthus Therapeutics (DNTH) Operating Income Comparison	02/14/2025
7	Dianthus Therapeutics (DNTH) Revenue Comparison	02/13/2025

	Title
0	ARTICLES

Trade Ideas

Select ideas related to DNTH.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
GEHC_4302026_Dip_Buyer_FCFYield	04302026	GEHC	GE HealthCare Technologies	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	0.0%	0.0%	0.0%
IQV_4302026_Dip_Buyer_FCFYield	04302026	IQV	IQVIA	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	0.0%	0.0%	0.0%
UHS_4302026_Dip_Buyer_FCFYield	04302026	UHS	Universal Health Services	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	0.0%	0.0%	0.0%
ABT_4302026_Dip_Buyer_ValueBuy	04302026	ABT	Abbott Laboratories	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	0.0%	0.0%	0.0%
ZBIO_4302026_Insider_Buying_45D_2Buy_200K	04302026	ZBIO	Zenas BioPharma	Insider	Insider Buys 45DStrong Insider Buying Companies with multiple insider buys in the last 45 days	0.0%	0.0%	0.0%

Recent Active Movers

Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
IMVT	Immunovant	6.5	35.3%	39.9%
TE	T1 Energy	1.9	26.5%	30.2%
NVTS	Navitas Semiconductor	5.1	18.3%	222.0%
SLS	SELLAS Life Sciences	1.3	18.2%	137.9%
ALAB	Astera Labs	48.7	17.7%	72.8%
GH	Guardant Health	14.8	17.1%	12.6%
FCEL	FuelCell Energy	1.0	16.5%	176.6%
HIVE	HIVE Digital Technologies	0.9	15.5%	50.0%
KURA	Kura Oncology	0.9	15.4%	-0.5%
ENVX	Enovix	1.4	15.0%	-13.0%

Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
HAS	Hasbro	12.4	-8.8%	8.8%
AXTI	AXT	4.7	-7.3%	539.8%
NTNX	Nutanix	12.1	-6.7%	-12.9%
DUOL	Duolingo	5.0	-6.4%	-39.1%
XZO	Exzeo	1.2	-6.2%	-47.1%
HPK	HighPeak Energy	1.0	-6.2%	60.8%
REPX	Riley Exploration Permian	0.8	-5.9%	50.7%
WTI	W&T Offshore	0.7	-5.9%	175.8%
CRK	Comstock Resources	4.2	-5.3%	-38.1%
KOS	Kosmos Energy	1.4	-5.3%	231.7%

Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
TE	T1 Energy	1.9	55.1%	30.2%
FBYD	Falcons Beyond Global	0.6	41.8%	-6.9%
HIVE	HIVE Digital Technologies	0.9	40.2%	50.0%
SLS	SELLAS Life Sciences	1.3	37.4%	137.9%
SG	Sweetgreen	1.1	36.9%	33.3%
ARX	Accelerant	3.7	33.2%	2.1%
STUB	Stubhub	3.5	33.0%	-26.1%
RAMP	LiveRamp	2.4	32.0%	28.5%
SEDG	SolarEdge Technologies	3.4	31.4%	94.9%
RDW	Redwire	2.5	28.9%	94.3%

Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
LWLG	Lightwave Logic	1.6	-35.8%	260.8%
BTGO	BitGo	0.9	-31.8%	-56.1%
OPTU	Optimum Communications	0.3	-29.8%	-60.5%
DSGN	Design Therapeutics	0.7	-28.9%	18.3%
IDR	Idaho Strategic Resources	0.6	-28.8%	-9.6%
AAOI	Applied Optoelectronics	11.6	-25.9%	374.1%
PSFE	Paysafe	0.4	-24.1%	-12.4%
USAS	Americas Gold And Silver	1.6	-23.2%	9.0%
CRVS	Corvus Pharmaceuticals	1.0	-23.0%	58.3%
HYMC	Hycroft Mining	2.8	-21.9%	43.3%

Top Gainers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
MXL	MaxLinear	8.5	187.2%	455.2%
BAND	Bandwidth	1.8	144.1%	275.1%
WOLF	Wolfspeed	1.6	137.3%	236.7%
FCEL	FuelCell Energy	1.0	113.1%	176.6%
INOD	Innodata	3.0	105.1%	85.9%
XMTR	Xometry	4.7	95.6%	54.3%
VPG	Vishay Precision	1.3	85.1%	161.6%
INTC	Intel	604.7	79.5%	222.4%
SLS	SELLAS Life Sciences	1.3	78.3%	137.9%
PCT	PureCycle Technologies	2.1	77.3%	38.1%

Top Losers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
CAR	Avis Budget	5.4	-78.6%	19.1%
EMBC	Embecta	0.2	-66.5%	-73.9%
FWRD	Forward Air	0.3	-63.5%	-66.3%
OPTU	Optimum Communications	0.3	-60.8%	-60.5%
CABO	Cable One	0.3	-59.7%	-58.3%
TRDA	Entrada Therapeutics	0.3	-53.8%	-41.2%
PSIX	Power Solutions International	0.9	-51.1%	-35.3%
ERAS	Erasca	3.2	-50.4%	198.9%
BETR	Better Home & Finance	0.4	-47.7%	-25.3%
BRBR	BellRing Brands	1.1	-45.5%	-66.4%

Peer Comparisons

Peers to compare with:

Financials

	DNTH	JNJ	AMGN	VRTX	REGN	IONS	Median
Name	Dianthus.	Johnson .	Amgen	Vertex P.	Regenero.	Ionis Ph.
Mkt Price	88.72	229.32	331.57	430.44	649.76	75.06	280.44
Mkt Cap	4.3	552.4	179.0	109.4	67.6	12.4	88.5
Rev LTM	1	96,362	37,220	12,218	14,920	1,058	13,569
Op Inc LTM	-191	25,792	10,568	4,662	3,843	-352	4,252
FCF LTM	-130	17,413	8,597	3,710	3,791	-978	3,751
FCF 3Y Avg	-88	18,074	8,870	1,977	3,561	-629	2,769
CFO LTM	-130	22,870	10,756	4,241	5,013	-911	4,627
CFO 3Y Avg	-88	23,615	10,348	2,401	4,568	-579	3,485

Growth & Margins

	DNTH	JNJ	AMGN	VRTX	REGN	IONS	Median
Name	Dianthus.	Johnson .	Amgen	Vertex P.	Regenero.	Ionis Ph.
Rev Chg LTM	-79.5%	7.9%	9.1%	10.1%	5.9%	47.5%	8.5%
Rev Chg 3Y Avg	-	4.4%	12.5%	9.9%	6.4%	24.9%	9.9%
Rev Chg Q	-60.2%	9.9%	5.8%	7.8%	19.0%	87.0%	8.9%
QoQ Delta Rev Chg LTM	-34.4%	2.3%	1.3%	1.8%	4.0%	12.1%	2.1%
Op Inc Chg LTM	-63.2%	20.7%	41.9%	1,214.0%	-2.4%	25.4%	23.1%
Op Inc Chg 3Y Avg	-	5.7%	8.8%	364.1%	-6.3%	6.9%	6.9%
Op Mgn LTM	-14,318.0%	26.8%	28.4%	38.2%	25.8%	-33.3%	26.3%
Op Mgn 3Y Avg	-5,974.6%	25.6%	24.6%	24.1%	28.1%	-49.8%	24.4%
QoQ Delta Op Mgn LTM	-5,578.7%	-0.4%	3.7%	0.2%	-0.1%	7.2%	0.1%
CFO/Rev LTM	-9,751.9%	23.7%	28.9%	34.7%	33.6%	-86.1%	26.3%
CFO/Rev 3Y Avg	-4,144.2%	26.2%	30.7%	21.5%	32.6%	-65.9%	23.9%
FCF/Rev LTM	-9,766.8%	18.1%	23.1%	30.4%	25.4%	-92.4%	20.6%
FCF/Rev 3Y Avg	-4,151.0%	20.1%	26.4%	17.7%	25.5%	-71.8%	18.9%

Valuation

	DNTH	JNJ	AMGN	VRTX	REGN	IONS	Median
Name	Dianthus.	Johnson .	Amgen	Vertex P.	Regenero.	Ionis Ph.
Mkt Cap	4.3	552.4	179.0	109.4	67.6	12.4	88.5
P/S	3,189.7	5.7	4.8	9.0	4.5	11.7	7.3
P/Op Inc	-22.3	21.4	16.9	23.5	17.6	-35.1	17.3
P/EBIT	-22.3	21.3	15.2	21.6	13.0	-51.2	14.1
P/E	-24.5	26.3	23.0	25.2	15.3	-37.8	19.1
P/CFO	-32.7	24.2	16.6	25.8	13.5	-13.6	15.1
Total Yield	-4.1%	6.1%	7.3%	4.0%	7.1%	-2.6%	5.0%
Dividend Yield	0.0%	2.3%	2.9%	0.0%	0.6%	0.0%	0.3%
FCF Yield 3Y Avg	-7.6%	4.1%	5.2%	1.8%	4.3%	-8.4%	3.0%
D/E	0.0	0.1	0.3	0.0	0.0	0.2	0.1
Net D/E	-0.3	0.1	0.3	-0.0	-0.1	0.0	-0.0

Returns

	DNTH	JNJ	AMGN	VRTX	REGN	IONS	Median
Name	Dianthus.	Johnson .	Amgen	Vertex P.	Regenero.	Ionis Ph.
1M Rtn	-3.5%	-0.6%	-4.6%	-2.0%	-13.2%	0.3%	-2.7%
3M Rtn	86.9%	-5.9%	-12.0%	-8.5%	-17.8%	-8.7%	-8.6%
6M Rtn	117.5%	14.6%	-1.1%	2.2%	-7.2%	1.4%	1.8%
12M Rtn	364.3%	53.4%	24.2%	-3.7%	6.3%	117.8%	38.8%
3Y Rtn	13,449.2%	57.8%	62.7%	26.0%	-13.7%	91.5%	60.3%
1M Excs Rtn	-6.8%	-3.8%	-8.4%	-6.6%	-18.2%	-4.8%	-6.7%
3M Excs Rtn	70.1%	-15.0%	-19.4%	-16.6%	-25.0%	-18.0%	-17.3%
6M Excs Rtn	103.2%	4.8%	-12.3%	-12.2%	-18.8%	-8.9%	-10.6%
12M Excs Rtn	335.8%	29.9%	-0.8%	-27.0%	-15.0%	95.9%	14.6%
3Y Excs Rtn	12,494.6%	-22.5%	-22.5%	-56.2%	-92.5%	27.4%	-22.5%

FDIC Bank Data

Bank Capital

null

Bank Deposits

null

Bank Assets

null

Bank Loans

null

FDA Approved Drugs Data

Expand for Morenull

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2025	2024	2023	2022	2021
Period End	3/31/2026	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021
Filing Date	5/5/2026	3/9/2026	3/11/2025	3/21/2024	5/15/2023	5/15/2023
Key Financials
Total Revenue	1	2	6	3	6	1
EBITDA	-191	-178	-101	-48	-30	-13
Operating Income	-191	-178	-102	-48	-30	-13
Net Income	-174	-162	-85	-44	-28	-13
EPS	-4.13	-4.20	-2.55	-8.45	-1.92	-0.88
Growth Rates
Total Revenue Growth	-79.5%	-67.3%	120.6%	-56.0%	334.8%	-
EBITDA Growth	-63.5%	-75.0%	-112.2%	-61.8%	-125.9%	-
Operating Income Growth	-63.2%	-74.7%	-111.5%	-62.2%	-127.0%	-
Net Income Growth	-72.4%	-91.1%	-95.1%	-53.0%	-117.2%	-
Margins
EBITDA Margin	-14290.3%	-8718.3%	-1627.1%	-1692.1%	-460.6%	-886.6%
Operating Income Margin	-14318.0%	-8739.3%	-1633.7%	-1704.7%	-462.9%	-886.6%
Net Income Margin	-12998.5%	-7973.3%	-1362.8%	-1541.2%	-443.8%	-888.1%
Cash & Debt
Total Cash	1,111	404	275	174	75	8
Total Debt	1	1	1	1	1	0
Net Debt / (Cash)	-1,110	-403	-274	-173	-75	-8
Cash Flows
Net Cash from Operations	-130	-129	-78	-37	-29	-10
Free Cash from Operations	-130	-129	-78	-37	-29	-10
Returns to Shareholders
Dividends	0	-0	-0	-0	-0	-0
Share Repurchases	-0	-0	-0	-0	-0	-0

$ Mil \| FY: 12/31	2026Q1	2025Q4	2025Q3	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2
Period End	3/31/2026	12/31/2025	9/30/2025	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023
Filing Date	5/5/2026	3/9/2026	11/5/2025	8/7/2025	5/12/2025	3/11/2025	11/7/2024	8/8/2024	5/9/2024	3/21/2024	11/9/2023	8/8/2024
Key Financials Quarterly
Total Revenue	0	0	0	0	1	1	2	2	1	0	1	1
Ebitda	-46	-69	-40	-35	-33	-32	-30	-22	-18	-13	-16	-12
Operating Income	-47	-70	-40	-35	-33	-32	-30	-22	-18	-13	-16	-12
Net Income	-41	-64	-37	-32	-30	-28	-25	-18	-14	-11	-15	-11
EPS	-0.85	-1.43	-0.97	-0.88	-0.82	-0.81	-0.74	-0.51	-0.54	-0.71	-3.78	-0.75
Key Financials TTM
Total Revenue TTM	1	2	3	5	7	6	5	4	3	3	4	4
Ebitda TTM	-191	-178	-140	-129	-117	-101	-82	-68	-58	-48	-46	-38
Operating Income TTM	-191	-178	-140	-130	-117	-102	-83	-69	-58	-48	-46	-38
Net Income TTM	-174	-162	-126	-115	-101	-85	-67	-57	-50	-44	-43	-36
Growth Rates Quarterly
Total Revenue Growth	-60.2%	-78.6%	-81.8%	-89.6%	33.1%	190.2%	135.1%	92.3%	83.6%	-61.1%	-21.2%	-
EBITDA Growth	-40.6%	-118.1%	-34.9%	-57.6%	-86.3%	-147.7%	-90.0%	-89.0%	-133.3%	-20.8%	-89.9%	-
Operating Income Growth	-40.3%	-117.9%	-34.7%	-57.3%	-85.9%	-146.3%	-89.7%	-88.6%	-132.3%	-21.2%	-90.9%	-
Net Income Growth	-38.4%	-126.6%	-46.0%	-79.6%	-114.7%	-169.2%	-70.5%	-58.1%	-93.9%	-4.4%	-89.7%	-
Margins Quarterly
EBITDA Margin	-10033.9%	-24452.1%	-10148.7%	-18045.6%	-2841.3%	-2401.1%	-1371.3%	-1185.9%	-2029.4%	-2812.5%	-1696.1%	-1206.6%
Operating Income Margin	-10050.3%	-24486.3%	-10173.7%	-18096.9%	-2852.7%	-2406.9%	-1376.6%	-1191.8%	-2041.6%	-2835.0%	-1705.5%	-1215.3%
Net Income Margin	-8819.4%	-22687.3%	-9284.1%	-16388.1%	-2537.5%	-2144.8%	-1159.0%	-945.1%	-1573.0%	-2311.4%	-1597.7%	-1149.6%
Cash & Debt
Total Cash	1,111	404	403	257	263	275	281	361	377	174	190	-
Total Debt	1	1	1	1	1	1	0	0	0	1	1	0
Net Debt / (Cash)	-1,110	-403	-401	-256	-262	-274	-281	-360	-377	-173	-189	-
Cash Flows Quarterly
FCF from Operations	-29	-47	-31	-24	-28	-27	-21	-15	-15	-12	-10	-5
Cash Flows TTM
FCF from Operations TTM	-130	-129	-110	-100	-91	-78	-63	-51	-42	-37	-34	-
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	-39.7%	-65.1%	-38.6%	-49.4%	-49.0%	-50.4%	-58.9%	-74.8%	-71.9%	-60.9%	-92.6%	-
Return on Invested Capital (ROIC) TTM
ROIC TTM	-40.8%	-41.6%	-33.6%	-46.0%	-43.3%	-40.2%	-40.8%	-57.9%	-58.7%	-56.6%	-67.5%	-

Segment Financials

Revenue by Segment

$ Mil	2025	2024	2023	2022
Developing next-generation therapies to transform the treatment of severe autoimmune diseases	6	3	6	1
Total	6	3	6	1

Net Income by Segment

$ Mil	2025	2024	2023	2022
Developing next-generation therapies to transform the treatment of severe autoimmune diseases	-85	-44
Total	-85	-44

Price Behavior

Price Behavior

Market Price	$88.72
Market Cap ($ Bil)	4.0
First Trading Date	06/21/2018
Distance from 52W High	-7.4%
	50 Days	200 Days
DMA Price	$85.82	$51.25
DMA Trend	up	up
Distance from DMA	3.4%	73.1%
	3M	1YR
Volatility	65.7%	65.4%
Downside Capture	-11.42	38.63
Upside Capture	221.82	210.87
Correlation (SPY)	22.2%	21.9%

DNTH Betas & Captures as of 4/30/2026

	1M	2M	3M	6M	1Y	3Y
Beta	1.64	1.45	1.53	1.06	1.14	-0.17
Up Beta	1.49	1.34	1.88	2.21	1.20	1.19
Down Beta	0.04	0.31	0.91	1.25	0.70	1.63
Up Capture	121%	342%	316%	208%	320%	361%
Bmk +ve Days	15	22	31	66	141	428
Stock +ve Days	12	24	34	64	125	378
Down Capture	526%	47%	38%	-77%	57%	-136%
Bmk -ve Days	4	18	30	56	108	321
Stock -ve Days	10	19	30	60	121	361

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Based On 1-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with DNTH
DNTH	366.5%	65.4%	2.62	-
Sector ETF (XLV)	11.5%	14.7%	0.52	22.4%
Equity (SPY)	26.2%	12.1%	1.62	21.7%
Gold (GLD)	40.2%	26.8%	1.24	12.2%
Commodities (DBC)	46.2%	18.7%	1.89	-6.8%
Real Estate (VNQ)	11.1%	13.4%	0.54	13.5%
Bitcoin (BTCUSD)	-27.4%	41.8%	-0.65	13.1%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 5-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with DNTH
DNTH	-10.9%	89.2%	0.27	-
Sector ETF (XLV)	5.4%	14.6%	0.19	16.7%
Equity (SPY)	14.1%	17.0%	0.65	18.8%
Gold (GLD)	19.5%	18.0%	0.89	1.6%
Commodities (DBC)	11.1%	19.4%	0.46	4.0%
Real Estate (VNQ)	4.0%	18.8%	0.11	13.3%
Bitcoin (BTCUSD)	9.1%	55.6%	0.37	10.4%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 10-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with DNTH
DNTH	-8.2%	86.8%	0.27	-
Sector ETF (XLV)	9.6%	16.5%	0.47	24.2%
Equity (SPY)	15.5%	17.9%	0.74	25.5%
Gold (GLD)	13.1%	16.0%	0.68	4.0%
Commodities (DBC)	7.9%	17.9%	0.36	8.3%
Real Estate (VNQ)	5.4%	20.7%	0.23	19.7%
Bitcoin (BTCUSD)	67.1%	66.9%	1.06	9.6%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date	4302026
Short Interest: Shares Quantity	6.6 Mil
Short Interest: % Change Since 4152026	-0.2%
Average Daily Volume	0.5 Mil
Days-to-Cover Short Interest	14.1 days
Basic Shares Quantity	48.0 Mil
Short % of Basic Shares	13.6%

Returns Analyses

	Title
0	How Low Can Dianthus Therapeutics Stock Really Go?

Earnings Returns History

Expand for More

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
5/5/2026	0.2%	-4.5%
1/12/2026	2.4%	15.5%	33.1%
10/16/2025	-0.6%	-7.6%	-1.9%
8/7/2025	-2.0%	5.7%	66.1%
3/11/2025	-6.3%	-11.3%	-30.2%
11/7/2024	-2.8%	-14.7%	-18.9%
8/8/2024	2.8%	11.5%	4.2%
3/21/2024	14.3%	7.4%	-16.8%
...
SUMMARY STATS
# Positive	12	10	9
# Negative	5	7	7
Median Positive	2.8%	6.6%	8.1%
Median Negative	-2.0%	-10.4%	-18.9%
Max Positive	14.3%	15.5%	66.1%
Max Negative	-6.3%	-14.7%	-34.7%

	Forward Returns
5/5/2026	0.2%	-4.5%
1/12/2026	2.4%	15.5%	33.1%
10/16/2025	-0.6%	-7.6%	-1.9%
8/7/2025	-2.0%	5.7%	66.1%
3/11/2025	-6.3%	-11.3%	-30.2%
11/7/2024	-2.8%	-14.7%	-18.9%
8/8/2024	2.8%	11.5%	4.2%
3/21/2024	14.3%	7.4%	-16.8%
11/9/2023	0.8%	0.4%	-28.8%
11/3/2022	4.9%	-11.4%	8.1%
8/4/2022	4.0%	3.1%	7.4%
3/8/2022	7.1%	10.2%	12.9%
11/4/2021	2.8%	-10.4%	-34.7%
8/5/2021	1.7%	3.8%	4.9%
3/3/2021	11.6%	8.8%	0.3%
11/5/2020	-0.9%	-0.9%	11.7%
8/6/2020	0.6%	2.4%	-1.5%
SUMMARY STATS
# Positive	12	10	9
# Negative	5	7	7
Median Positive	2.8%	6.6%	8.1%
Median Negative	-2.0%	-10.4%	-18.9%
Max Positive	14.3%	15.5%	66.1%
Max Negative	-6.3%	-14.7%	-34.7%

SEC Filings

Expand for More

Report Date	Filing Date	Filing
03/31/2026	05/05/2026	10-Q
12/31/2025	03/09/2026	10-K
09/30/2025	11/05/2025	10-Q
06/30/2025	08/07/2025	10-Q
03/31/2025	05/12/2025	10-Q
12/31/2024	03/11/2025	10-K
09/30/2024	11/07/2024	10-Q
06/30/2024	08/08/2024	10-Q
03/31/2024	05/09/2024	10-Q
12/31/2023	03/21/2024	10-K
09/30/2023	11/09/2023	10-Q
12/31/2022	05/15/2023	S-4

Recent Forward Guidance [BETA]

Latest: Q1 2026 Earnings Reported 5/5/2026

null

Prior: Q4 2025 Earnings Reported 1/12/2026

null

Insider Activity

Expand for More

#	Owner	Title	Holding	Action	Filing Date	Price	Shares	Form
1	Soteropoulos, Paula		Direct	Sell	5112026	85.47	599	Form
2	Savitz, Ryan	EVP, CFO & CBO	Direct	Sell	4102026	89.84	8,224	Form
3	Savitz, Ryan	EVP, CFO & CBO	Direct	Sell	4012026	83.00	114,367	Form
4	Soteropoulos, Paula		Direct	Sell	4012026	80.11	599	Form
5	Soteropoulos, Paula		Direct	Sell	3262026	78.05	27,594	Form

DNTH Trade Sentinel

Stock Conviction

null

CONVICTION RATIONALE

null

STOCK ARCHETYPE

null

Looking for high-conviction positions with a better risk/reward profile? See what's currently in the Trefis High Quality Portfolio.

INVESTMENT THESIS

null

Mechanism: null

Supporting Evidence:

PRIMARY RISK

null

Mechanism: null

Supporting Evidence:

Key KPI Watchlist

KPI	Threshold	Rationale

Core Investment Debate

BULL VIEW

CORE TENSION

PREVAILING SENTIMENT

BEAR VIEW

Next 6 months: Risks and Catalysts

Timeline	Event & Metric To Watch

Key Events in Last 6 Months

Date	Event	Stock Impact

Risk Management

Position Sizing

null

Diversification Alternatives

How Is The Market Pricing DNTH?

What will confirm the thesis

What will damage the thesis

Noise: Real but irrelevant to thesis

Repricing Catalyst

What DNTH Makes & Who Pays

TTM figures based on

DNTH Evolution: Price Return by Era

① Structure

② Volume / Momentum

③ Catalyst

Combined Score

0 / 12

1 Price Structure & Trend · ▾

2 Momentum ▾

3 Relative Strength vs. SPY ▾

4 Institutional Footprint & Volume ▾

5 Volatility ▾

6 Key Price Levels Range · Vol ▾

7 Earnings Reaction History ▾

8 How the Verdict Is Derived Three Pillars ▾

Pillar	Score
① Structure	0
② Vol / Mom	0
③ Catalyst	0

ℹ Bull Pillars: 0 · Bear Pillars: 0 · Combined Score: 0 →

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

Biotechnology Resources

Fierce Biotech

Nature Biotechnology

Genetic Engineering & Biotechnology News

Biotechnology Innovation Organization

BioWorld

BioTechniques

HBS Biotechnology Publications

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Dianthus Therapeutics (DNTH)

Market Price (5/21/2026): $89.0 | Market Cap: $4.3 BilSector: Health Care | Industry: Biotechnology

Dianthus Therapeutics (DNTH)

Market Price (5/21/2026): $89.0Market Cap: $4.3 BilSector: Health CareIndustry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Valuation, Metrics & Events

Price Chart

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

In The Past

Preserve Wealth

Asset Allocation

About Dianthus Therapeutics (DNTH)

Key Risks to Dianthus Therapeutics (DNTH)

Interactive Breakdown

Better Bets vs. Dianthus Therapeutics (DNTH)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

Top Gainers

Top Losers

Top Gainers

Top Losers

Top Gainers

Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

FDA Approved Drugs Data

Financials

Segment Financials

Price Behavior

Based On 1-Year Data

Based On 5-Year Data

Based On 10-Year Data

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Recent Forward Guidance [BETA]

Insider Activity

DNTH Trade Sentinel

null

CONVICTION RATIONALE

STOCK ARCHETYPE

INVESTMENT THESIS

PRIMARY RISK

BULL VIEW

CORE TENSION

PREVAILING SENTIMENT

BEAR VIEW

Position Sizing

null

Market Price (5/21/2026): $89.0 | Market Cap: $4.3 Bil
Sector: Health Care | Industry: Biotechnology

Market Price (5/21/2026): $89.0
Market Cap: $4.3 Bil
Sector: Health Care
Industry: Biotechnology